Robert R. Seltzer is Director & 10% at NephroGenex, Inc. (NRX). They have made 1 open-market trade across 1 company since 2014, most recently 2014-02-14.
CIK 0001597198
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $9.5M since 2014, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| NRX | 3,038,505 | $426K |
Shares reported on the most recent Form 4, priced at the 2014-02-19 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| NRX | BUY | 2014-02-14 | 2014-02-19 | $12.00 | $9.5M | -32.1% | +3.8% | +3.8% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.